Top

Published in:

01-07-2012 | Review

Refractory celiac disease: from bench to bedside

Authors: Georgia Malamut, Bertrand Meresse, Christophe Cellier, Nadine Cerf-Bensussan

Published in: Seminars in Immunopathology | Issue 4/2012

Abstract

Refractory celiac disease is defined by the persistence of symptoms of malnutrition and intestinal villous atrophy for more than 6–12 months despite strict gluten-free diet in celiac patients. Diagnosis of this rare condition is made after excluding other causes of chronic small intestinal inflammation and villous atrophy and inadvertent intake of gluten. Over the past 15 years, multidisciplinary approaches have been developed to assess the mechanism of resistance to the diet, and two distinct entities have been delineated. Type II refractory celiac disease (RCD) can be defined as a low-grade intraepithelial lymphoma. RCD II is characterised by a massive accumulation of abnormal IEL that display an aberrant hybrid NK/T cell phenotype, contain clonal T cell rearrangement(s) and can mediate a cytolytic attack of the gut epithelium. This condition has a severe prognosis, largely due to the frequent transformation of RCDII IEL into overt aggressive enteropathy-type-associated T cell lymphoma. In contrast, in type I RCD, intestinal lymphocytes have a normal phenotype, and this generally milder condition remains often difficult to differentiate from uncomplicated CD except for the resistance to gluten-free diet (GFD). Several mechanisms may underlie resistance to gluten. Herein, we review the distinctive characteristics of RCD I and RCD II, the mechanisms underlying the onset of resistance to GFD, the risk of developing high grade lymphoma and possible clues to improve their treatment.

Meresse B, Malamut G, Cerf-Bensussan N (2012) Celiac disease: an immunological jigsaw. Immunity 36(6):907–915

Vahedi K, Mascart F, Mary JY, Laberenne JE, Bouhnik Y, Morin MC, Ocmant A, Velly C, Colombel JF, Matuchansky C (2003) Reliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease. Am J Gastroenterol 98(5):1079–1087PubMedCrossRef

Akram S, Murray JA, Pardi DS, Alexander GL, Schaffner JA, Russo PA, Abraham SC (2007) Adult autoimmune enteropathy (2007) Mayo clinic rochester experience. Clin Gastroenterol Hepatol 5(11):1282–1290PubMedCrossRef

Malamut G, Verkarre V, Suarez F, Viallard JF, Lascaux AS, Cosnes J, Bouhnik Y, Lambotte O, Bechade D, Ziol M, Lavergne A, Hermine O, Cerf-Bensussan N, Cellier C (2010) The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. Am J Gastroenterol 105(10):2262–2275PubMedCrossRef

Carbonnel F, d’Almagne H, Lavergne A, Matuchansky C, Brouet JC, Sigaux F, Beaugerie L, Nemeth J, Coffin B, Cosnes J, Gendre JP, Rambaud JC (1999) The clinicopathological features of extensive small intestinal CD4 T cell infiltration. Gut 45(5):662–667PubMedCrossRef

Khokhar N, Gill ML (2004) Tropical sprue: revisited. J Pak Med Assoc 54(3):133–134PubMed

Malamut G, Afchain P, Verkarre V, Lecomte T, Amiot A, Damotte D, Bouhnik Y, Colombel JF, Delchier JC, Allez M, Cosnes J, Lavergne-Slove A, Meresse B, Trinquart L, Macintyre E, Radford-Weiss I, Hermine O, Brousse N, Cerf-Bensussan N, Cellier C (2009) Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology 136(1):81–90PubMedCrossRef

Rubio-Tapia A, Kelly DG, Lahr BD, Dogan A, Wu TT, Murray JA (2009) Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 136(1):99–107PubMedCrossRef

Green PH, Cellier C (2007) Celiac disease. N Engl J Med 357(17):1731–1743PubMedCrossRef

10.

Cellier C, Patey N, Mauvieux L, Jabri B, Delabesse E, Cervoni JP, Burtin ML, Guy-Grand D, Bouhnik Y, Modigliani R, Barbier JP, Macintyre E, Brousse N, Cerf-Bensussan N (1998) Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology 114(3):471–481PubMedCrossRef

11.

Cellier C, Delabesse E, Helmer C, Patey N, Matuchansky C, Jabri B, Macintyre E, Cerf-Bensussan N, Brousse N, French Coeliac Disease Study Group (2000) Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. Lancet 356(9225):203–208PubMedCrossRef

12.

Cerf-Bensussan N, Jarry A, Brousse N, Lisowska-Grospierre B, Guy-Grand D, Griscelli C (1987) A monoclonal antibody (HML-1) defining a novel membrane molecule present on human intestinal lymphocytes. Eur J Immunol 17(9):1279–1285PubMedCrossRef

13.

Cepek KL, Shaw SK, Parker CM, Russell GJ, Morrow JS, Rimm DL, Brenner MB (1994) Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin. Nature 372:190–193PubMedCrossRef

14.

Hue S, Mention JJ, Monteiro RC, Zhang S, Cellier C, Schmitz J, Verkarre V, Fodil N, Bahram S, Cerf-Bensussan N, Caillat-Zucman S (2004) A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 21(3):367–377PubMedCrossRef

15.

Verkarre V, Asnafi V, Lecomte T, Patey Mariaud-de Serre N, Leborgne M, Grosdidier E, Le Bihan C, Macintyre E, Cellier C, Cerf-Bensussan N, Brousse N (2003) Refractory coeliac sprue is a diffuse gastrointestinal disease. Gut 52(2):205–211PubMedCrossRef

16.

Perfetti V, Brunetti L, Biagi F, Ciccocioppo R, Bianchi PI, Corazza GR (2012) TCR beta clonality improves diagnostic yield of TCRgamma clonality in refractory celiac disease. J Clin Gastroenterol. doi:10.1097/MCG.0b013e31823eff20

17.

Isaacson P, Wright DH (1978) Malignant histiocytosis of the intestine. Its relationship to malabsorption and ulcerative jejunitis. Hum Pathol 9(6):661–677PubMedCrossRef

18.

Mubarak A, Oudshoorn JH, Kneepkens CM, Butler JC, Schreurs MW, Mulder CJ, Houwen RH (2011) A child with refractory coeliac disease. J Pediatr Gastroenterol Nutr 53(2):216–218PubMedCrossRef

19.

West J (2009) Celiac disease and its complications: a time traveller's perspective. Gastroenterology 136(1):32–34PubMedCrossRef

20.

Roshan B, Leffler DA, Jamma S, Dennis M, Sheth S, Falchuk K, Najarian R, Goldsmith J, Tariq S, Schuppan D, Kelly CP (2011) The incidence and clinical spectrum of refractory celiac disease in a north american referral center. Am J Gastroenterol 106(5):923–928PubMedCrossRef

21.

Daum S, Ipczynski R, Schumann M, Wahnschaffe U, Zeitz M, Ullrich R (2009) High rates of complications and substantial mortality in both types of refractory sprue. Eur J Gastroenterol Hepatol 21(1):66–70PubMedCrossRef

22.

Al-Toma A, Verbeek WH, Hadithi M, von Blomberg BM, Mulder CJ (2007) Survival in refractory coeliac disease and enteropathy associated T cell lymphoma: retrospective evaluation of single centre experience. Gut 56(10):1373–1378PubMedCrossRef

23.

Cottone M, Termini A, Oliva L, Magliocco A, Marrone C, Orlando A, Pinzone F, Di Mitri R, Rosselli M, Rizzo A, Pagliaro L (1999) Mortality and causes of death in celiac disease in a Mediterranean area. Dig Dis Sci 44(12):2538–2541PubMedCrossRef

24.

Corrao G, Corazza GR, Bagnardi V, Brusco G, Ciacci C, Cottone M, Sategna Guidetti C, Usai P, Cesari P, Pelli MA, Loperfido S, Volta U, Calabro A, Certo M (2001) Mortality in patients with coeliac disease and their relatives: a cohort study. Lancet 358(9279):356–361PubMedCrossRef

25.

Askling J, Linet M, Gridley G, Halstensen TS, Ekstrom K, Ekbom A (2002) Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology 123(5):1428–1435PubMedCrossRef

26.

Verbeek WH, Van De Water JM, Al-Toma A, Oudejans JJ, Mulder CJ, Coupe VM (2008) Incidence of enteropathy-associated T-cell lymphoma: a nation-wide study of a population-based registry in the Netherlands. Scand J Gastroenterol 43(11):1322–1328CrossRef

27.

Sharaiha RZ, Lebwohl B, Reimers L, Bhagat G, Green PH, Neugut AI (2012) Increasing incidence of enteropathy-associated T-cell lymphoma in the United States, 1973–2008. Cancer. doi:10.1002/cncr.26700

28.

Telega G, Bennet TR, Werlin S (2008) Emerging new clinical patterns in the presentation of celiac disease. Arch Pediatr Adolesc Med 162(2):164–168PubMedCrossRef

29.

Green PH (2009) Mortality in celiac disease, intestinal inflammation, and gluten sensitivity. Jama 302(11):1225–1226PubMedCrossRef

30.

Deleeuw RJ, Zettl A, Klinker E, Haralambieva E, Trottier M, Chari R, Ge Y, Gascoyne RD, Chott A, Muller-Hermelink HK, Lam WL (2007) Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology 132(5):1902–1911PubMedCrossRef

31.

Tio M, Cox MR, Eslick GD, Meta-analysis (2012) Coeliac disease and the risk of all-cause mortality, any malignancy and lymphoid malignancy. Aliment Pharmacol Ther 35(5):540–551PubMedCrossRef

32.

Spencer J, Cerf-Bensussan N, Jarry A, Brousse N, Guy-Grand D, Krajewski AS, Isaacson PG (1988) Enteropathy-associated T cell lymphoma (malignant histiocytosis of the intestine) is recognized by a monoclonal antibody (HML-1) that defines a membrane molecule on human mucosal lymphocytes. Am J Pathol 132(1):1–5PubMed

33.

Verkarre V, Romana SP, Cellier C, Asnafi V, Mention JJ, Barbe U, Nusbaum S, Hermine O, Macintyre E, Brousse N, Cerf-Bensussan N, Radford-Weiss I (2003) Recurrent partial trisomy 1q22-q44 in clonal intraepithelial lymphocytes in refractory celiac sprue. Gastroenterology 125(1):40–46PubMedCrossRef

34.

Malamut G, Verkarre V, Meresse B, Macintyre E, Brousse N, Cerf-Bensussan N, Cellier C (2008) High rate of abnormal intestinal intraepithelial lymphocytes is predictive of extra-digestive diffusion in refractory coeliac disease. (Abstract) Gut 57(suppl II):A 30

35.

Egan LJ, Walsh SV, Stevens FM, Connolly CE, Egan EL, McCarthy CF (1995) Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era. J Clin Gastroenterol 21(2):123–129PubMedCrossRef

36.

Gale J, Simmonds PD, Mead GM, Sweetenham JW, Wright DH (2000) Enteropathy-type intestinal t-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 18(4):795–803PubMed

37.

Daum S, Ullrich R, Heise W, Dederke B, Foss HD, Stein H, Thiel E, Zeitz M, Riecken EO (2003) Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the german study group on intestinal non-Hodgkin's lymphoma. J Clin Oncol 21(14):2740–2746PubMedCrossRef

38.

Malamut G, Chandesris O, Verkarre V, Macintyre E, Brousse N, Meresse B, Bouhnik Y, Allez M, Berger A, Jian R, Cerf-Bensussan N, Hermine O, Cellier C (2010) Tumour mass reduction surgery improves the prognosis of enteropathy associated T cell lymphoma. (Abstract) Gastroenterology 138 (6) (suppl 1)

39.

Howell MD, Austin RK, Kelleher D, Nepom GT, Kagnoff MF (1986) An HLA-D region restriction fragment length polymorphism associated with celiac disease. J Exp Med 164(1):333–338PubMedCrossRef

40.

Sollid LM, Markussen G, Ek J, Gjerde H, Vartdal F, Thorsby E (1989) Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. J Exp Med 169(1):345–350PubMedCrossRef

41.

Fallang LE, Bergseng E, Hotta K, Berg-Larsen A, Kim CY, Sollid LM (2009) Differences in the risk of celiac disease associated with HLA-DQ2.5 or HLA-DQ2.2 are related to sustained gluten antigen presentation. Nat Immunol 10(10):1096–1101PubMedCrossRef

42.

Sollid LM, Qiao SW, Anderson RP, Gianfrani C, Koning F (2012) Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by HLA-DQ molecules. Immunogenetics64 (6):455–460

43.

Abadie V, Sollid LM, Barreiro LB, Jabri B (2011) Integration of genetic and immunological insights into a model of celiac disease pathogenesis. Annu Rev Immunol 29:493–525PubMedCrossRef

44.

Vader W, Stepniak D, Kooy Y, Mearin L, Thompson A, van Rood JJ, Spaenij L, Koning F (2003) The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc Natl Acad Sci U S A 100(21):12390–12395PubMedCrossRef

45.

Al-Toma A, Goerres MS, Meijer JW, Pena AS, Crusius JB, Mulder CJ (2006) Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma. Clin Gastroenterol Hepatol 4(3):315–319PubMedCrossRef

46.

Smyth DJ, Plagnol V, Walker NM, Cooper JD, Downes K, Yang JH, Howson JM, Stevens H, McManus R, Wijmenga C, Heap GA, Dubois PC, Clayton DG, Hunt KA, van Heel DA, Todd JA (2008) Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med 359(26):2767–2777PubMedCrossRef

47.

Hunt KA, Zhernakova A, Turner G, Heap GA, Franke L, Bruinenberg M, Romanos J, Dinesen LC, Ryan AW, Panesar D, Gwilliam R, Takeuchi F, McLaren WM, Holmes GK, Howdle PD, Walters JR, Sanders DS, Playford RJ, Trynka G, Mulder CJ, Mearin ML, Verbeek WH, Trimble V, Stevens FM, O'Morain C, Kennedy NP, Kelleher D, Pennington DJ, Strachan DP, McArdle WL, Mein CA, Wapenaar MC, Deloukas P, McGinnis R, McManus R, Wijmenga C, van Heel DA (2008) Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 40(4):395–402PubMedCrossRef

48.

Dubois PC, Trynka G, Franke L, Hunt KA, Romanos J, Curtotti A, Zhernakova A, Heap GA, Adany R, Aromaa A, Bardella MT, van den Berg LH, Bockett NA, de la Concha EG, Dema B, Fehrmann RS, Fernandez-Arquero M, Fiatal S, Grandone E, Green PM, Groen HJ, Gwilliam R, Houwen RH, Hunt SE, Kaukinen K, Kelleher D, Korponay-Szabo I, Kurppa K, MacMathuna P, Maki M, Mazzilli MC, McCann OT, Mearin ML, Mein CA, Mirza MM, Mistry V, Mora B, Morley KI, Mulder CJ, Murray JA, Nunez C, Oosterom E, Ophoff RA, Polanco I, Peltonen L, Platteel M, Rybak A, Salomaa V, Schweizer JJ, Sperandeo MP, Tack GJ, Turner G, Veldink JH, Verbeek WH, Weersma RK, Wolters VM, Urcelay E, Cukrowska B, Greco L, Neuhausen SL, McManus R, Barisani D, Deloukas P, Barrett JC, Saavalainen P, Wijmenga C, van Heel DA (2010) Multiple common variants for celiac disease influencing immune gene expression. Nat Genet 42(5):295–302PubMedCrossRef

49.

Trynka G, Hunt KA, Bockett NA, Romanos J, Mistry V, Szperl A, Bakker SF, Bardella MT, Bhaw-Rosun L, Castillejo G, de la Concha EG, de Almeida RC, Dias KR, van Diemen CC, Dubois PC, Duerr RH, Edkins S, Franke L, Fransen K, Gutierrez J, Heap GA, Hrdlickova B, Hunt S, Izurieta LP, Izzo V, Joosten LA, Langford C, Mazzilli MC, Mein CA, Midah V, Mitrovic M, Mora B, Morelli M, Nutland S, Nunez C, Onengut-Gumuscu S, Pearce K, Platteel M, Polanco I, Potter S, Ribes-Koninckx C, Ricano-Ponce I, Rich SS, Rybak A, Santiago JL, Senapati S, Sood A, Szajewska H, Troncone R, Varade J, Wallace C, Wolters VM, Zhernakova A, Thelma BK, Cukrowska B, Urcelay E, Bilbao JR, Mearin ML, Barisani D, Barrett JC, Plagnol V, Deloukas P, Wijmenga C, van Heel DA (2011) Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 43(12):1193–1201PubMedCrossRef

50.

Fina D, Sarra M, Caruso R, Del Vecchio BG, Pallone F, MacDonald TT, Monteleone G (2008) Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease. Gut 57(7):887–892PubMedCrossRef

51.

Bodd M, Raki M, Tollefsen S, Fallang LE, Bergseng E, Lundin KE, Sollid LM (2010) HLA-DQ2 restricted gluten-reactive T cells produce IL-21 but not IL-17 or IL-22. Mucosal Immunol 3(6):594–601PubMedCrossRef

52.

Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP, Berzofsky JA, Leonard WJ (2005) Synergy of IL-21 and IL-15 in regulating CD8⁺ T cell expansion and function. J Exp Med 201(1):139–148PubMedCrossRef

53.

Devalliere J, Charreau B (2011) The adaptor LNK (SH2B3): an emerging regulator in vascular cells and a link between immune and inflammatory signaling. Biochem Pharmacol 82(10):1391–1402PubMedCrossRef

54.

Holmes GK, Prior P, Lane MR, Pope D, Allan RN (1989) Malignancy in coeliac disease—effect of a gluten free diet. Gut 30(3):333–338PubMedCrossRef

55.

Olen O, Askling J, Ludvigsson JF, Hildebrand H, Ekbom A, Smedby KE (2011) Coeliac disease characteristics, compliance to a gluten free diet and risk of lymphoma by subtype. Dig Liver Dis 43(11):862–868PubMedCrossRef

56.

Biagi F, Corazza GR (2010) Mortality in celiac disease. Nat Rev Gastroenterol Hepatol 7(3):158–162PubMedCrossRef

57.

Plot L, Amital H (2009) Infectious associations of celiac disease. Autoimmun Rev 8(4):316–319PubMedCrossRef

58.

Bourliere M, Oules V, Perrier H, Mengotti C (2001) Onset of coeliac disease and interferon treatment. Lancet 357(9258):803–804PubMedCrossRef

59.

Westhoff TH, Vergoulidou M, Loddenkemper C, Schwartz S, Hofmann J, Schneider T, Zidek W, van der Giet M (2009) Chronic norovirus infection in renal transplant recipients. Nephrol Dial Transplant 24(3):1051–1053PubMedCrossRef

60.

Foxman EF, Iwasaki A (2011) Genome-virome interactions: examining the role of common viral infections in complex disease. Nat Rev Microbiol 9(4):254–264PubMedCrossRef

61.

Gough DJ, Messina NL, Clarke CJ, Johnstone RW, Levy DE (2012) Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 36(2):166–174PubMedCrossRef

62.

Colpitts SL, Stoklasek TA, Plumlee CR, Obar JJ, Guo C, Lefrancois L (2012) Cutting edge: the role of IFN-alpha receptor and MYD88 signaling in induction of IL-15 expression in vivo. J Immunol 188:2483–2487PubMedCrossRef

63.

Dafik L, Albertelli M, Stamnaes J, Sollid LM, Khosla C (2012) Activation and inhibition of transglutaminase 2 in mice. PLoS One 7(2):e30642PubMedCrossRef

64.

Vella AT, Dow S, Potter TA, Kappler J, Marrack P (1998) Cytokine-induced survival of activated T cells in vitro and in vivo. Proc Natl Acad Sci U S A 95(7):3810–3815PubMedCrossRef

65.

Vakiani E, Arguelles-Grande C, Mansukhani MM, Lewis SK, Rotterdam H, Green PH, Bhagat G (2010) Collagenous sprue is not always associated with dismal outcomes: a clinicopathological study of 19 patients. Mod Pathol 23(1):12–26PubMedCrossRef

66.

Xiao Z, Dasari VM, Kirby DF, Bronner M, Plesec TP, Lashner BA (2009) Collagenous sprue: a case report and literature review. Gastroenterol Hepatol (N Y) 5(6):418–424

67.

Daum S, Foss HD, Schuppan D, Riecken EO, Zeitz M, Ullrich R (2006) Synthesis of collagen I in collagenous sprue. Clin Gastroenterol Hepatol 4(10):1232–1236PubMedCrossRef

68.

Cosnes J, Cellier C, Viola S, Colombel JF, Michaud L, Sarles J, Hugot JP, Ginies JL, Dabadie A, Mouterde O, Allez M, Nion-Larmurier I (2008) Incidence of autoimmune diseases in celiac disease: protective effect of the gluten-free diet. Clin Gastroenterol Hepatol 6(7):753–758PubMedCrossRef

69.

Meresse B, Chen Z, Ciszewski C, Tretiakova M, Bhagat G, Krausz TN, Raulet DH, Lanier LL, Groh V, Spies T, Ebert EC, Green PH, Jabri B (2004) Coordinated induction by IL-15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21(3):357–366PubMedCrossRef

70.

Ogasawara K, Hamerman JA, Ehrlich LR, Bour-Jordan H, Santamaria P, Bluestone JA, Lanier LL (2004) NKG2D blockade prevents autoimmune diabetes in nod mice. Immunity 20(6):757–767PubMedCrossRef

71.

Mention JJ, Ben Ahmed M, Begue B, Barbe U, Verkarre V, Asnafi V, Colombel JF, Cugnenc PH, Ruemmele FM, McIntyre E, Brousse N, Cellier C, Cerf-Bensussan N, Interleukin 15 (2003) A key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 125(3):730–745PubMedCrossRef

72.

Di Sabatino A, Ciccocioppo R, Cupelli F, Cinque B, Millimaggi D, Clarkson MM, Paulli M, Cifone MG, Corazza GR (2006) Epithelium derived interleukin 15 regulates intraepithelial lymphocyte TH1 cytokine production, cytotoxicity, and survival in coeliac disease. Gut 55(4):469–477PubMedCrossRef

73.

Ben Ahmed M, Meresse B, Arnulf B, Barbe U, Mention J, Verkarre V, Allez M, Cellier C, Hermine O, Cerf-Bensussan N (2007) Inhibition of TGF-β signaling by IL-15: A new role for IL-15 in the loss of immune homeostasis in celiac disease. Gastroenterology 132(3):994–1008CrossRef

74.

Li MO, Sanjabi S, Flavell RA (2006) Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25(3):455–471PubMedCrossRef

75.

Marie JC, Liggitt D, Rudensky AY (2006) Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity 25(3):441–454PubMedCrossRef

76.

Wildin RS, Freitas A (2005) IPEX and FOXP3: clinical and research perspectives. J Autoimmun 25(Suppl):56–62PubMedCrossRef

77.

Ben Ahmed M, Belhadj Hmida N, Moes N, Buyse S, Abdeladhim M, Louzir H, Cerf-Bensussan N (2009) Il-15 renders conventional lymphocytes resistant to suppressive functions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway. J Immunol 182(11):6763–6770PubMedCrossRef

78.

Hmida NB, Ahmed MB, Moussa A, Rejeb MB, Said Y, Kourda N, Meresse B, Abdeladhim M, Louzir H, Cerf-Bensussan N (2012) Impaired control of effector T cells by regulatory T cells: a clue to loss of oral tolerance and autoimmunity in celiac disease? Am J Gastroenterol 107(4):604–611PubMedCrossRef

79.

DePaolo RW, Abadie V, Tang F, Fehlner-Peach H, Hall JA, Wang W, Marietta EV, Kasarda DD, Waldmann TA, Murray JA, Semrad C, Kupfer SS, Belkaid Y, Guandalini S, Jabri B (2011) Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature 471(7337):220–224PubMedCrossRef

80.

Bergamaschi C, Rosati M, Jalah R, Valentin A, Kulkarni V, Alicea C, Zhang GM, Patel V, Felber BK, Pavlakis GN (2008) Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J Biol Chem 283(7):4189–4199PubMedCrossRef

81.

Fehniger TA, Caligiuri MA (2001) Interleukin 15: biology and relevance to human disease. Blood 97(1):14–32PubMedCrossRef

82.

Malamut G, El Machhour R, Montcuquet N, Martin-Lanneree S, Dusanter-Fourt I, Verkarre V, Mention JJ, Rahmi G, Kiyono H, Butz EA, Brousse N, Cellier C, Cerf-Bensussan N, Meresse B (2010) Il-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest 120(6):2131–2143PubMedCrossRef

83.

Ohta N, Hiroi T, Kweon MN, Kinoshita N, Jang MH, Mashimo T, Miyazaki J, Kiyono H (2002) Il-15-dependent activation-induced cell death-resistant TH1 type CD8 alpha beta + NK1.1+ T cells for the development of small intestinal inflammation. J Immunol 169(1):460–468PubMed

84.

Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, Florea SM, Freud AG, Robinson ML, Durbin J, Caligiuri MA (2001) Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med 193(2):219–231PubMedCrossRef

85.

Tjon JM, Verbeek WH, Kooy-Winkelaar YM, Nguyen BH, van der Slik AR, Thompson A, Heemskerk MH, Schreurs MW, Dekking LH, Mulder CJ, van Bergen J, Koning F (2008) Defective synthesis or association of t-cell receptor chains underlies loss of surface T-cell receptor-CD3 expression in enteropathy-associated T-cell lymphoma. Blood 112(13):5103–5110PubMedCrossRef

86.

Maiuri L, Ciacci C, Auricchio S, Brown V, Quaratino S, Londei M (2000) Interleukin 15 mediates epithelial changes in celiac disease. Gastroenterology 119(4):996–1006PubMedCrossRef

87.

Wang Y, Seidl T, Whittall T, Babaahmady K, Lehner T (2010) Stress-activated dendritic cells interact with CD4+ T cells to elicit homeostatic memory. Eur J Immunol 40 (6):1628–1638

88.

Rubio-Tapia A, Murray JA (2010) Classification and management of refractory coeliac disease. Gut 59(4):547–557PubMedCrossRef

89.

Goerres MS, Meijer JW, Wahab PJ, Kerckhaert JA, Groenen PJ, Van Krieken JH, Mulder CJ (2003) Azathioprine and prednisone combination therapy in refractory coeliac disease. Aliment Pharmacol Ther 18(5):487–494PubMedCrossRef

90.

Dray X, Joly F, Lavergne-Slove A, Treton X, Bouhnik Y, Messing B (2006) A severe but reversible refractory sprue. Gut 55(8):1210–1211PubMedCrossRef

91.

Al-Toma A, Goerres MS, Meijer JW, von Blomberg BM, Wahab PJ, Kerckhaert JA, Mulder CJ (2006) Cladribine therapy in refractory celiac disease with aberrant t cells. Clin Gastroenterol Hepatol 4(11):1322–1327PubMedCrossRef

92.

Al-Toma A, Visser OJ, van Roessel HM, von Blomberg BM, Verbeek WH, Scholten PE, Ossenkoppele GJ, Huijgens PC, Mulder CJ (2006) Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T-cells. Blood 109(5):2243–2249PubMedCrossRef

93.

Tack GJ, Wondergem MJ, Al-Toma A, Verbeek WH, Schmittel A, Machado MV, Perri F, Ossenkoppele GJ, Huijgens PC, Schreurs MW, Mulder CJ, Visser OJ (2011) Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy. Bone Marrow Transplant 46(6):840–846PubMedCrossRef

94.

Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, Connell CA, Gruben D, Krishnaswami S, Wallenstein G, Wilkinson BE, Zwillich SH (2012) Phase IIb dose-ranging study of the oral Jak inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 64(3):617–629PubMedCrossRef

Title: Refractory celiac disease: from bench to bedside
Authors: Georgia Malamut
Bertrand Meresse
Christophe Cellier
Nadine Cerf-Bensussan
Publication date: 01-07-2012
Publisher: Springer-Verlag
Published in: Seminars in Immunopathology / Issue 4/2012
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-012-0322-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Intraepithelial lymphocytes in celiac disease immunopathology

Introduction: celiac disease

Animal models to study gluten sensitivity

The adaptive immune response in celiac disease

Celiac disease in children and adolescents: special considerations

Role of transglutaminase 2 in celiac disease pathogenesis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials